Investment
InnovationsKapital and a group of private investors have invested SEK 30 million (about $5 million) to increase the production capacity of Isconnova’s proprietary ISCOM vaccine adjuvant technology. Funding will expand marketing and accelerate the development of animal and human vaccines.
Isconnova, established in 2000 by scientists from the Swedish Agricultural University, has developed the ISCOM technology, a platform to deliver vaccines safely and effectively. The technology is based on a matrix formed of cage-like aponin structures in which antigens are incorporated. Such adjuvant systems, says Isconnova, makes vaccines more protective and longer-lasting.
With its high production capacity in Uppsala, Isconnova is supplying its matrix adjuvants to corporate partners for use in animal vaccines. Johan Rask and Ulf Tossman, of InnovationsKapital, said: “We feel very excited about Isconnova’s future.”
ISCOM is a vaccine adjuvant for horse vaccines in Europe and has been licensed to corporations such as Intervet, Schering Plough, Pfizer and Crucell. Isconnova aims to apply its adjuvant to the development of dog, cat and livestock vaccines, as well as investigate the use of ISCOM technology in human vaccines.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
